Circulating T cell subsets are associated with clinical outcome
of anti-VEGF-based 1st-line treatment of metastatic colorectal
cancer patients: a prospective study with focus on primary
tumor sidedness

J 2019

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness

BENCSIKOVA, B., E. BUDINSKA, I. SELINGEROVÁ, K. PILATOVA, L. FEDOROVA et. al.

Basic information

Original name

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness

Authors

BENCSIKOVA, B. (guarantor), E. BUDINSKA, I. SELINGEROVÁ (203 Czech Republic), K. PILATOVA, L. FEDOROVA, K. GREPLOVA, R. NENUTIL, Dalibor VALÍK (203 Czech Republic, belonging to the institution), Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), M.A. SHEARD and L. ZDRAZILOVA DUBSKA

Edition

BMC Cancer, London, BioMed Central, 2019, 1471-2407

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.150

RIV identification code

RIV/00216224:14110/19:00123168

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s12885-019-5909-5

UT WoS

000475706700010

Keywords (in Czech)

Metastatic colorectal cancer; T cell subsets; Regulatory T cells; Antitumor immune response; Anti-VEGF; Primary colorectal carcinoma sidedness

Keywords in English

Metastatic colorectal cancer; T cell subsets; Regulatory T cells; Antitumor immune response; Anti-VEGF; Primary colorectal carcinoma sidedness

Abstract

V originále

BackgroundIn a prospective study with long-term follow-up, we analyzed circulating T cell subsets in patients with metastatic colorectal cancer (mCRC) in the context of primary tumor sidedness, KRAS status, and clinical outcome. Our primary goal was to investigate whether baseline levels of circulating T cell subsets serve as a potential biomarker of clinical outcome of mCRC patients treated with an anti-VEGF-based regimen.MethodsThe study group consisted of 36 patients with colorectal adenocarcinoma who started first-line chemotherapy with bevacizumab for metastatic disease. We quantified T cell subsets including Tregs and CD8(+) T cells in the peripheral blood prior to therapy initiation. Clinical outcome was evaluated as progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).Results1) mCRC patients with KRAS wt tumors had higher proportions of circulating CD8(+) cytotoxic T cells among all T cells but also higher measures of T regulatory (Treg) cells such as absolute count and a higher proportion of Tregs in the CD4(+) subset. 2) A low proportion of circulating Tregs among CD4(+) cells, and a high CD8:Treg ratio at initiation of VEGF-targeting therapy, were associated with favorable clinical outcome. 3) In a subset of patients with primarily right-sided mCRC, superior PFS and OS were observed when the CD8:Treg ratio was high.ConclusionsThe baseline level of circulating immune cells predicts clinical outcome of 1st-line treatment with the anti-VEGF angio/immunomodulatory agent bevacizumab. Circulating immune biomarkers, namely the CD8:Treg ratio, identified patients in the right-sided mCRC subgroup with favorable outcome following treatment with 1st-line anti-VEGF treatment.

Links

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

BENCSIKOVA, B., E. BUDINSKA, I. SELINGEROVÁ, K. PILATOVA, L. FEDOROVA, K. GREPLOVA, R. NENUTIL, Dalibor VALÍK, Radka OBERMANNOVÁ, M.A. SHEARD and L. ZDRAZILOVA DUBSKA. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. BMC Cancer. London: BioMed Central, 2019, vol. 19, No 687, p. 1-9. ISSN 1471-2407. Available from: https://dx.doi.org/10.1186/s12885-019-5909-5.

@article{1808237,
   author = {Bencsikova, B. and Budinska, E. and Selingerová, I. and Pilatova, K. and Fedorova, L. and Greplova, K. and Nenutil, R. and Valík, Dalibor and Obermannová, Radka and Sheard, M.A. and Zdrazilova Dubska, L.},
   article_location = {London},
   article_number = {687},
   doi = {http://dx.doi.org/10.1186/s12885-019-5909-5},
   keywords = {Metastatic colorectal cancer; T cell subsets; Regulatory T cells; Antitumor immune response; Anti-VEGF; Primary colorectal carcinoma sidedness},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   note = {RIV/00209805:_____/19:00078214!RIV20-MSM-00209805},
   title = {Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5909-5},
   volume = {19},
   year = {2019}
}

TY  - JOUR
ID  - 1808237
AU  - Bencsikova, B. - Budinska, E. - Selingerová, I. - Pilatova, K. - Fedorova, L. - Greplova, K. - Nenutil, R. - Valík, Dalibor - Obermannová, Radka - Sheard, M.A. - Zdrazilova Dubska, L.
PY  - 2019
TI  - Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness
JF  - BMC Cancer
VL  - 19
IS  - 687
SP  - 1-9
EP  - 1-9
PB  - BioMed Central
SN  - 14712407
N1  - RIV/00209805:_____/19:00078214!RIV20-MSM-00209805
KW  - Metastatic colorectal cancer
KW  - T cell subsets
KW  - Regulatory T cells
KW  - Antitumor immune response
KW  - Anti-VEGF
KW  - Primary colorectal carcinoma sidedness
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5909-5
N2  - BackgroundIn a prospective study with long-term follow-up, we analyzed circulating T cell subsets in patients with metastatic colorectal cancer (mCRC) in the context of primary tumor sidedness, KRAS status, and clinical outcome. Our primary goal was to investigate whether baseline levels of circulating T cell subsets serve as a potential biomarker of clinical outcome of mCRC patients treated with an anti-VEGF-based regimen.MethodsThe study group consisted of 36 patients with colorectal adenocarcinoma who started first-line chemotherapy with bevacizumab for metastatic disease. We quantified T cell subsets including Tregs and CD8(+) T cells in the peripheral blood prior to therapy initiation. Clinical outcome was evaluated as progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).Results1) mCRC patients with KRAS wt tumors had higher proportions of circulating CD8(+) cytotoxic T cells among all T cells but also higher measures of T regulatory (Treg) cells such as absolute count and a higher proportion of Tregs in the CD4(+) subset. 2) A low proportion of circulating Tregs among CD4(+) cells, and a high CD8:Treg ratio at initiation of VEGF-targeting therapy, were associated with favorable clinical outcome. 3) In a subset of patients with primarily right-sided mCRC, superior PFS and OS were observed when the CD8:Treg ratio was high.ConclusionsThe baseline level of circulating immune cells predicts clinical outcome of 1st-line treatment with the anti-VEGF angio/immunomodulatory agent bevacizumab. Circulating immune biomarkers, namely the CD8:Treg ratio, identified patients in the right-sided mCRC subgroup with favorable outcome following treatment with 1st-line anti-VEGF treatment.
ER  -

BENCSIKOVA, B., E. BUDINSKA, I. SELINGEROVÁ, K. PILATOVA, L. FEDOROVA, K. GREPLOVA, R. NENUTIL, Dalibor VALÍK, Radka OBERMANNOVÁ, M.A. SHEARD and L. ZDRAZILOVA DUBSKA. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. \textit{BMC Cancer}. London: BioMed Central, 2019, vol.~19, No~687, p.~1-9. ISSN~1471-2407. Available from: https://dx.doi.org/10.1186/s12885-019-5909-5.

Detailed Information on Publication Record